Edition:
India

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

22.55EUR
19 Jan 2018
Change (% chg)

€0.55 (+2.50%)
Prev Close
€22.00
Open
€22.05
Day's High
€22.65
Day's Low
€21.80
Volume
27,694
Avg. Vol
29,839
52-wk High
€23.88
52-wk Low
€13.88

Chart for

About

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactur... (more)
No analyst recommendations are available for .

Overall

Beta: 0.62
Market Cap(Mil.): €999.67
Shares Outstanding(Mil.): 39.57
Dividend: 0.05
Yield (%): 0.18

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

12:46am IST

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

19 Jan 2018

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Dec 2017

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

14 Nov 2017

Takeover of plasma firm Biotest by China's Creat hits wall in U.S

FRANKFURT Chinese investor Creat Group Corp has withdrawn and will rework its application for U.S. approval of a planned takeover of Biotest amid concerns over national security, the German blood plasma products maker said, sending its shares sharply lower.

07 Nov 2017

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

07 Nov 2017

BRIEF-Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling

* ‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​

07 Nov 2017

BRIEF-Curetis partners with Biotest to support academic PEPPER Pentaglobin Peritonitis trial

* CURETIS PARTNERS WITH BIOTEST TO SUPPORT ACADEMIC PEPPER PENTAGLOBIN® PERITONITIS TRIAL WITH UNYVERO IAI APPLICATION

15 Aug 2017

BRIEF-Biotest H1 result swings to loss of 17.8 million euros

* H1 REVENUE FROM CONTINUING OPERATIONS FELL 11 PERCENT TO 247.1 MILLION EUR

14 Aug 2017

Earnings vs. Estimates